WuXi Biologics' Subsidiary WuXi Vaccines Signed Long-Term Vaccine Manufacturing Contract with a Global Vaccine Leader

SHANGHAI,Feb. 18,2020 -- WuXi Biologics ("WuXi Bio") (2269.HK),a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery,development and manufacturing,announced that WuXi Vaccines,its joint venture with Shanghai Hile Bio-technology(603718.SH),has entered into a strategic partnership with a global vaccine leader and signed a 20-year vaccine manufacturing contract valued approximately $3 billion USD,pursuant to which WuXi Vaccines will build a dedicated facility and supply a commercial vaccine products for the global market.

WuXi Vaccines Facility in Ireland

Per the contract signed,WuXi Vaccines will build an integrated vaccine manufacturing facility including drug substance manufacturing (DS),drug product manufacturing (DP),Manufacture Science and Technology Labs (MS&T) as well as Quality Control labs (QC). The facility will be dedicated to manufacture one ofits partner's vaccine products for the global market. The new facility is expected to be operational in 2022.

In Nov 2019,WuXi Vaccines announced 240 million USD investment to build the new vaccine manufacturing facility in Ireland. The facility is located within the WuXi Biologics Campus adjacent to the "Factory of the Future" biologics drug substance manufacturing facility which is scheduled for commercial manufacturing in 2021.

WuXi Vaccines is a joint venture company established between WuXi Biologics and Shanghai Hile Bio-technology (stock code: 603718.SH). The business model of WuXi Vaccines is to build world-class integrated platforms and CDMO model to enable global companies to develop and manufacture vaccines.

"This is a historic moment for WuXi Biologics and WuXi Vaccines as well as for the global vaccine industry. Due to process complexity,extensive analytic testing and rigorous regulatory standards,vaccines are difficult to manufacture and process and quality control are extremely critical for the quality of the product. This partnership with a global vaccine leader to exclusively manufacture a vaccine for the global market,first of its kind in the industry,is a further testimony to the technical strengths and premier quality demonstrated by WuXi Vaccines," commented Dr. Chris Chen,CEO of WuXi Biologics and Chairman of WuXi Vaccines,"Vaccine CDMO is one of the next growth areas for WuXi Biologics. Once this project is initiated,our vaccine business will contribute substantially to the growth of WuXi Biologics. WuXi Biologics together with WuXi Vaccines will continue to provide our global partners with a robust and premier-quality supply chain network to produce high quality biologic and vaccine products to benefit patients worldwide and to protect human being globally,initially with therapeutic proteins and now with vaccines."

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK),a Hong Kong-listed company,is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover,develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and strong value proposition to our global clients. As of June 30,2019,there were a total of 224 integrated projects,including 106 projects in pre-clinical development stage,102 projects in early-phase (phase I and II) clinical development,15 projects in late-phase (phase III) development and one project in commercial manufacturing. With total estimated capacity for biopharmaceutical production planned in China,Ireland,Singapore,and the U.S. exceeding 280,000 liters by 2022,we will provide our biomanufacturing partners with a robust and premier-quality global supply chain network. For more information on WuXi Biologics,please visit www.wuxibiologics.com.

Photo - https://photos.prnasia.com/prnh/20200218/2722961-1?lang=0